Industry’s Lesson On Non-Inferiority Margins In Anti-Infective Trials: Use 10%
Executive Summary
If industry is to learn anything from the three-day Anti-Infective Drugs Advisory Committee meeting on how to correctly use non-inferiority margins in trials, it is to adhere to the panel's recommendation of 10 percent (at least for now)
You may also be interested in...
FDA Emphasizes Pathogen ID In Complicated Intra-Abdominal Infection Guidance
The agency checked another box on the list of guidances anticipated by developers of antibiotic drugs with the Oct. 1 release of a draft guidance on treatments for complicated intra-abdominal infections.
PhRMA Urges FDA To Set Non-Inferiority Margin For Skin Infection Drugs
FDA should provide more specificity on the non-inferiority margin it expects clinical trials for acute bacterial skin and skin structure infection (ABSSSI) treatments to satisfy, pharmaceutical companies and infectious disease specialists say.
PhRMA Urges FDA To Set Non-Inferiority Margin For Skin Infection Drugs
FDA should provide more specificity on the non-inferiority margin it expects clinical trials for acute bacterial skin and skin structure infection (ABSSSI) treatments to satisfy, pharmaceutical companies and infectious disease specialists say.